Treatment of CTCL is determined by disease stage. Early stage CTCL frequently responds to skin-directed therapy, while advanced stage CTCL generally requires systemic therapies. Combination therapy may be required in many patients.
Due to the chronic nature of this disease, patients will usually require repeat treatment and chronic maintenance regimens.7 This list is not comprehensive; some therapies may not be listed below.
Specially designed for medical professionals to use in their practice.
See top Opinion Leaders address FAQs about THERAKOS™ Photopheresis
Methoxsalen Sterile Solution is indicated for extracorporeal administration with the THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment.
Methoxsalen should be used only by physicians who have special training in the THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis Systems. Methoxsalen is contraindicated in patients exhibiting idiosyncratic reactions to psoralen compounds, patients with a specific history of a light sensitive disease, or patients with aphakia.
THERAKOS™ Photopheresis is not appropriate for patients who cannot tolerate extracorporeal volume loss or shifts, or patients with coagulation disorders. See Important Safety Information for additional details.